I was once told that you couldn't make money from FDA, Phase III or other meaningful biotech decisions by an old publishing group I worked for.
Since leaving them behind, I've closed about 25 winners and only 4 losers since October 2012, including a five-day 250% gain on MAP Pharmaceuticals.
Those that can't think outside the box are doomed…

